Balchem Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 7, 2014, details the closing of Balchem Corporation's acquisition of Performance Chemicals & Ingredients Company (PCI), d/b/a SensoryEffects, and the entry into a new senior secured credit facility to finance the transaction. PCI is a supplier of customized food and beverage ingredient systems headquartered in St. Louis, Missouri.
Key Financial Metrics and Transaction Details
- Acquisition Price: Aggregate purchase price of $567 million in cash (including repayment of PCI's indebtedness).
- Cash Paid to Sellers: Approximately $459.8 million at closing.
- Escrow Amount: $27.5 million deposited for post-closing adjustments and indemnification obligations.
- Debt Repaid: Approximately $75.5 million of PCI's existing indebtedness.
- Transaction Costs: Approximately $6.3 million of unpaid costs paid by Balchem.
- New Credit Facility: Total availability of $450 million consisting of a $350 million Term Loan and a $100 million Revolving Credit Facility.
- Drawdowns: The full $350 million Term Loan and $50 million of the Revolving Credit Facility were drawn to finance the acquisition.
- Term Loan Repayment: Quarterly installments of $8.75 million principal plus accrued interest; final maturity in five years.
Material Changes Versus Prior Period
Balchem terminated its previous Amended and Restated Credit Agreement dated June 2, 2011, which was held by PCI and its lenders (including Texas Capital Bank and The PrivateBank and Trust Company). This was replaced by the new $450 million Senior Credit Facilities with a syndicate of lenders including Bank of America, N.A., JPMorgan Chase Bank, N.A., and others. The company's capital structure has significantly changed due to the $400 million in new borrowings utilized for the acquisition.
Guidance, Covenants, and Risks
Financial Covenants: The new Credit Agreement imposes the following covenants, commencing after the first fiscal quarter ending post-closing:
- Maximum Consolidated Total Leverage Ratio: 4.00:1.00 initially, stepping down to 3.50:1.00 (Dec 31, 2014), 3.00:1.00 (Dec 31, 2015), and 2.75:1.00 (Dec 31, 2016).
- Minimum Consolidated Fixed Charge Coverage Ratio: 1.25:1.00 measured on a trailing twelve-month basis.
Interest Rates: Rates are variable based on LIBOR or Base Rate plus an Applicable Margin determined by the Consolidated Total Leverage Ratio (ranging from 1.25% to 2.00% for LIBOR loans).
Risks and Contingencies: Management highlights risks regarding the successful integration of PCI. The filing includes standard forward-looking statement disclaimers noting that actual results may differ materially from expectations. Pro forma financial information and PCI's standalone financial statements are not included in this filing but will be filed within 71 days.
Investor Verification Checklist
- Verify the final purchase price adjustments and the release of the $27.5 million escrow funds after the 18-month period.
- Monitor Balchem's ability to meet the initial 4.00:1.00 leverage ratio covenant in the first post-closing quarter.
- Review the upcoming 71-day amendment for PCI's financial statements and pro forma combined financial information.
- Assess the integration progress of PCI's operations and the retention of key management (Charles A. Nicolais and Mark Miller).
- Track the impact of the new $400 million debt load on future cash flows and interest expense.